专题：Radiopharmaceutical Chemistry and Applications

This cluster of papers focuses on the development, synthesis, and application of radiopharmaceuticals for PET and SPECT imaging, targeted therapy, radioimmunotherapy, and alpha particle therapy in cancer treatment. It covers topics such as coordinating radiometals, chelators, dosimetry, and the use of specific radionuclides for therapeutic purposes.
最新文献
Nomogram-based risk classification for predicting response to metastasis-directed stereotactic body radiotherapy in PSMA PET-staged oligorecurrent prostate cancer (PORTAL): an international, retrospective cohort study

article Full Text OpenAlex

Radiation as an immune modulator: mechanisms and implications for combination with immunotherapy

article Full Text OpenAlex

Linker Manipulation with Beta 3 ‐Amino Acids Potentiates the Efficacy and Safety of PSMA Radiopharmaceuticals

article Full Text OpenAlex

CO108 Evaluating the Impact of Censoring on Progression-Free Survival Comparisons of BCMA-Targeting Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

article Full Text OpenAlex

[18F]-Fluciclovine or [68Ga]-PSMA-11 Molecular Imaging To Guide Dose Escalation of Salvage Radiotherapy After Radical Prostatectomy for Prostate Cancer: The EMPIRE-2 Trial

article Full Text OpenAlex

Therapeutic Applications of Fibroblast Activation Protein (FAP)-Binding Radiopharmaceuticals: Review of Opportunities and Challenges

article Full Text OpenAlex

New Frontiers in ADC Analysis: Advances in Chromatography, Electrophoresis, and Mass Spectrometry

article Full Text OpenAlex

Exploratory Analysis of [68Ga]Ga-FAP-2286 PET/CT Quantitative Parameters for Predicting Response to [177Lu]Lu-FAP-2286 Therapy in Non-small Cell Lung Cancer

article Full Text OpenAlex

UAB/SNMMI Nuclear Medicine Therapy Intensive: Advancing Competence and Innovation in Radiopharmaceutical Therapy

article Full Text OpenAlex

The Role of Artificial Intelligence in Theranostics

article Full Text OpenAlex

近5年高被引文献
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology

article Full Text OpenAlex 522 FWCI136.3877

Radiotheranostics in oncology: current challenges and emerging opportunities

review Full Text OpenAlex 334 FWCI44.378

FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease

review Full Text OpenAlex 294 FWCI68.8336

Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade

review Full Text OpenAlex 286 FWCI39.0469

Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

article Full Text OpenAlex 285 FWCI41.0417

Advances in PET imaging of cancer

review Full Text OpenAlex 259 FWCI60.7201

[177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer

review Full Text OpenAlex 259 FWCI36.7855

Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)

review Full Text OpenAlex 245 FWCI64.4496

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

article Full Text OpenAlex 242 FWCI34.2067

Radiochemistry for positron emission tomography

review Full Text OpenAlex 241 FWCI56.0672